Clinical trial
Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus…
NCT00135941 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00135941 |
|---|---|
| Title | Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2) |
| Official title | Insulin Glargine Plus Insulin Glulisine MDI Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2) Evaluating Differences in Patient Reported Outcomes |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | insulin glargine, insulin glulisine |
| Enrollment | 582 |
| Start date | Aug 1, 2005 |
| Completion | Sep 1, 2007 |
| First posted | Aug 26, 2005 |
| Last update posted | Jun 4, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: